Rituximab Responsive Relapsing-Remitting IgG4 Anticontactin 1 Chronic Inflammatory Demyelinating Polyradiculoneuropathy Associated With Membranous Nephropathy: A Case Description and Brief Review.
Gauthier RemicheMarta Lamartine S MonteiroConcetta CatalanoJean-Michel HougardyEmilien DelmontJosé BoucrautNicolas MavroudakisPublished in: Journal of clinical neuromuscular disease (2022)
Nodal/paranodal IgG4-related chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) rarely involves anticontactin (CNTN1) subtype and exceptionally complicates with nephrotic syndrome. A 65-year-old man developed weakness, facial palsy, and balance impairment; after spontaneous recovery, he severely relapsed 1 month later. Electroneuromyography confirmed CIDP. Proteinorachy (462 mg/dL; N < 45), proteinuria (3.5 g/g creatine), and biopsy-proven membranous nephropathy were identified. Intravenous immunoglobulins, corticosteroids, and plasmaphereses did not allow recovery. Anti-CNTN1 immunoglobulin G4 (IgG4) assay was positive. Rituximab (375 mg/m2/week, 4 weeks) provided obvious improvement. Relapsing-remitting anti-CNTN1-CIDP co-occurring with nephrotic syndrome is exceptional, and its identification is essential because efficient therapies such as rituximab are available for this severe condition.
Keyphrases
- multiple sclerosis
- diffuse large b cell lymphoma
- hodgkin lymphoma
- disease activity
- chronic lymphocytic leukemia
- oxidative stress
- acute lymphoblastic leukemia
- acute myeloid leukemia
- systemic lupus erythematosus
- lymph node
- high throughput
- rheumatoid arthritis
- drug induced
- high dose
- cancer therapy
- early onset
- randomized controlled trial
- soft tissue
- multiple myeloma
- low dose
- neoadjuvant chemotherapy
- single cell
- bioinformatics analysis